Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in JAK inhibitor-naïve myelofibrosis
NCT05980806Phase 2Recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Apr 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, open-label trial of selinexor in myelofibrosis (MF) (2 arms), sponsored by Karyopharm Therapeutics Inc. Primary endpoint: Spleen Volume Reduction ≥35% at 24 weeks. Started Apr 2024; status: recruiting.
02
Drugs
selinexor
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05980806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05980806.